Enfortumab vedotin-话题@MedSci

#Enfortumab vedotin#

3篇内容 | 370人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2162678, encodeId=83a321626e803, content=<a href='/topic/show?id=290e10695580' target=_blank style='color:#2F92EE;'>#恩诺单抗#</a><a href='/topic/show?id=51c610641167' target=_blank style='color:#2F92EE;'>#Enfortumab vedotin#</a>（EV），<a href='/topic/show?id=07b7106393d5' target=_blank style='color:#2F92EE;'>#戈沙妥珠单抗#</a>(SG)，<a href='/topic/show?id=6848104291a8' target=_blank style='color:#2F92EE;'>#维迪西妥单抗#</a>（RC48）是三种<a href='/topic/show?id=b5f71041887c' target=_blank style='color:#2F92EE;'>#ADC类药物#</a>治疗<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a>, objectTitle=新型ADC和联合治疗用于尿路上皮癌：2023 ASCO-GU的最新进展, objectType=article, longId=785961, objectId=23f4e85961c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230809/1691588056834_6145188.png, objectUrl=/article/show_article.do?id=23f4e85961c9, replyNumber=0, likeNumber=51, createdTime=2023-10-14, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=23f4e85961c9, moduleTitle=新型ADC和联合治疗用于尿路上皮癌：2023 ASCO-GU的最新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23f4e85961c9)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2147211, encodeId=e691214e211b9, content=在<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a>转移过程中<a href='/topic/show?id=b711106410b6' target=_blank style='color:#2F92EE;'>#Nectin-4#</a>表达水平的降低与<a href='/topic/show?id=51c610641167' target=_blank style='color:#2F92EE;'>#Enfortumab vedotin#</a><a href='/topic/show?id=0650803e21a' target=_blank style='color:#2F92EE;'>#耐药#</a>相关, objectTitle=Clin Cancer Res：在尿路上皮癌转移过程中NECTIN-4表达水平的降低与Enfortumab vedotin耐药相关, objectType=article, longId=756284, objectId=084ce56284cb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230116/1673859383508_2110107.JPG, objectUrl=/article/show_article.do?id=084ce56284cb, replyNumber=1, likeNumber=52, createdTime=2023-07-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=084ce56284cb, moduleTitle=Clin Cancer Res：在尿路上皮癌转移过程中NECTIN-4表达水平的降低与Enfortumab vedotin耐药相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=084ce56284cb)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2147213, encodeId=122e214e2137f, content=<a href='/topic/show?id=51c610641167' target=_blank style='color:#2F92EE;'>#Enfortumab vedotin#</a>用于抗<a href='/topic/show?id=234613893a4' target=_blank style='color:#2F92EE;'>#PD-1#</a>治疗后的铂不适用的局部晚期或转移性<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a>的疗效可期！, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021514/1620985889700_2110107.png, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=58, createdTime=2023-07-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 侠胆医心

在尿路上皮癌转移过程中NECTIN-4表达水平的降低与Enfortumab vedotin耐药相关

2023-07-10发表于上海

(审核中...)

前往app查看评论内容

#恩诺单抗##Enfortumab vedotin#（EV），#戈沙妥珠单抗#(SG)，#维迪西妥单抗#（RC48）是三种#ADC类药物#治疗#尿路上皮癌#

新型ADC和联合治疗用于尿路上皮癌：2023 ASCO-GU的最新进展

2023-10-14发表于上海

(审核中...)

前往app查看评论内容

在#尿路上皮癌#转移过程中#Nectin-4#表达水平的降低与#Enfortumab vedotin##耐药#相关

Clin Cancer Res：在尿路上皮癌转移过程中NECTIN-4表达水平的降低与Enfortumab vedotin耐药相关

2023-07-10发表于上海

(审核中...)

前往app查看评论内容

#Enfortumab vedotin#用于抗#PD-1#治疗后的铂不适用的局部晚期或转移性#尿路上皮癌#的疗效可期！

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2023-07-10发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务